Catalyst Pharmaceuticals (CPRX) to Release Quarterly Earnings on Wednesday

Key Points

• Catalyst Pharmaceuticals is expected to announce its Q2 2025 earnings on August 6, with analysts predicting earnings of $0.57 per share and revenue of $140.42 million.
• The company’s stock opened at $21.01 and has a market capitalization of $2.56 billion, with a price-to-earnings ratio of 13.38.
• Catalyst Pharmaceuticals has received a "strong-buy" rating from Cantor Fitzgerald, with a consensus rating of "Buy" and an average target price of $32.83 from six investment analysts.

Catalyst Pharmaceuticals (NASDAQ:CPRX - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data after the market closes on Wednesday, August 6th. Analysts expect the company to announce earnings of $0.57 per share and revenue of $140.42 million for the quarter.

Catalyst Pharmaceuticals Stock Performance

CPRX stock traded down $0.21 on Friday, hitting $21.12. 999,536 shares of the company's stock were exchanged, compared to its average volume of 1,210,948. Catalyst Pharmaceuticals has a 12-month low of $15.34 and a 12-month high of $26.58. The firm has a 50 day moving average price of $22.63 and a two-hundred day moving average price of $22.85. The stock has a market cap of $2.58 billion, a P/E ratio of 13.45, a price-to-earnings-growth ratio of 0.87 and a beta of 0.70.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, June 5th. Six investment analysts have rated the stock with a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, Catalyst Pharmaceuticals currently has an average rating of "Buy" and a consensus price target of $32.83.

Insider Activity

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,000 shares of the business's stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $23.63, for a total transaction of $1,039,720.00. Following the sale, the insider owned 68,873 shares in the company, valued at approximately $1,627,468.99. The trade was a 38.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Preethi Sundaram sold 1,600 shares of the business's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total value of $42,272.00. Following the completion of the transaction, the insider directly owned 41,081 shares of the company's stock, valued at approximately $1,085,360.02. This trade represents a 3.75% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 247,924 shares of company stock worth $5,879,369. Company insiders own 10.40% of the company's stock.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Intech Investment Management LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 6.5% in the 1st quarter. Intech Investment Management LLC now owns 70,087 shares of the biopharmaceutical company's stock valued at $1,700,000 after buying an additional 4,261 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Catalyst Pharmaceuticals by 99.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 526,297 shares of the biopharmaceutical company's stock worth $12,763,000 after purchasing an additional 262,392 shares during the period. Goldman Sachs Group Inc. raised its holdings in Catalyst Pharmaceuticals by 11.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company's stock worth $76,035,000 after purchasing an additional 333,100 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Catalyst Pharmaceuticals by 5.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 72,052 shares of the biopharmaceutical company's stock worth $1,749,000 after purchasing an additional 3,800 shares during the period. Finally, Royal Bank of Canada raised its holdings in Catalyst Pharmaceuticals by 39.1% in the 1st quarter. Royal Bank of Canada now owns 213,469 shares of the biopharmaceutical company's stock worth $5,177,000 after purchasing an additional 60,040 shares during the period. Institutional investors and hedge funds own 79.22% of the company's stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.